These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22709717)

  • 21. Re: intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin.
    Kaplan SA
    J Urol; 2014 Jan; 191(1):157. PubMed ID: 24331494
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China.
    Sun YH; Liu ZY; Zhang ZS; Xu CL; Ji JT; Wu YY; Shao Y; Zhang LM
    Chin Med J (Engl); 2011 Jan; 124(1):56-60. PubMed ID: 21362308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
    Yuan RQ
    Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1147-51. PubMed ID: 23405801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy.
    Matthies AK; Tachikawa NJ
    Aviat Space Environ Med; 2013 Jan; 84(1):54-8. PubMed ID: 23305000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the combination of avodart and tamsulosin (CombAT) study.
    Woo H
    BJU Int; 2011 May; 107(9):1431. PubMed ID: 21518231
    [No Abstract]   [Full Text] [Related]  

  • 27. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
    Yuan JQ; Yang ZY; Mao C
    Eur Urol; 2012 Aug; 62(2):e35; author reply e36-8. PubMed ID: 22656724
    [No Abstract]   [Full Text] [Related]  

  • 29. Reply from Authors re: Steven A. Kaplan. Tadalafil for the Treatment of Benign Prostatic Hyperplasia: When the Moment Does Not Add Up. Eur Urol 2013;63:517-8: Tadalafil in the Treatment of Men with Lower Urinary Tract Symptoms and/or Erectile Dysfunction Symptoms.
    Giuliano F; Viktrup L
    Eur Urol; 2013 Mar; 63(3):519-20. PubMed ID: 23260653
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Reasons for prescription change of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2015 Apr; 193(4):1317. PubMed ID: 25890537
    [No Abstract]   [Full Text] [Related]  

  • 33. Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants.
    Nickel JC; Brock GB; Herschorn S; Dickson R; Henneges C; Viktrup L
    BJU Int; 2015 May; 115(5):815-21. PubMed ID: 25195970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Re: Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
    Seftel AD
    J Urol; 2012 Sep; 188(3):904-5. PubMed ID: 22883791
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
    Pande S; Hazra A; Kundu AK
    Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin.
    Cumpanas AA; Botoca M; Minciu R; Bucuras V
    Urology; 2013 Apr; 81(4):859-63. PubMed ID: 23375910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.
    Montorsi F; Roehrborn C; Garcia-Penit J; Borre M; Roeleveld TA; Alimi JC; Gagnier P; Wilson TH
    BJU Int; 2011 May; 107(9):1426-31. PubMed ID: 21348912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia.
    Yoshida M; Inadome A; Masunaga K; Nagata T; Yoshiyasu T
    Neurourol Urodyn; 2010 Sep; 29(7):1276-81. PubMed ID: 20878997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.